Tempo Therapeutics has been awarded a $2.25 million grant from the National Institutes of Health (NIH) to advance its MAP wound healing technology, the company announced.

The award directs federal research funding toward a platform squarely aimed at one of dermatology's most persistent problems: wounds that fail to close through standard care. Chronic and hard-to-heal wounds impose substantial morbidity and cost, and device- and material-based approaches that can accelerate closure remain an active area of development.

What is the MAP platform?

MAP is Tempo Therapeutics' wound healing technology, and the $2.25 million NIH grant is specifically designated to advance it toward clinical application. For dermatologists and wound care clinicians, the significance lies in what the funding enables: continued development of a technology intended to improve tissue repair outcomes where conventional dressings and standard of care fall short.

The company has not yet disclosed in the announcement the specific study endpoints, cohort size, or trial design that the grant will support. Those details will determine how quickly the technology moves from development toward evidence that matters at the bedside.

Why the funding matters for wound care

Wound healing sits at the intersection of dermatology, vascular medicine, and surgery. Patients with diabetes, venous insufficiency, and prolonged immobility represent large cohorts where healing delays drive infection risk, hospitalization, and amputation.

A $2.25 million NIH commitment signals that the MAP platform has cleared peer-review scrutiny at the federal funding level — a meaningful validation step for an early-stage technology, though distinct from demonstrated clinical efficacy in controlled trials.

What comes next

The grant funds advancement of the MAP wound healing technology, and the dermatology community will watch for subsequent disclosures on preclinical results, regulatory pathway, and any planned clinical studies. As those data emerge, Tempo Therapeutics' platform will face the central question for any wound healing innovation: whether it can measurably shorten time to closure in defined patient populations compared with standard care.